Tubulis GmbH’s Post

The recent Food & Drug Administration approval of Amtagvi by US-based Iovance Biotherapeutics is a groundbreaking milestone in cancer treatment. Specifically designed for metastatic melanoma patients who have exhausted standard treatments, Amtagvi employs TIL therapy, marking the first FDA-approved cellular treatment for solid tumours. Its fast-track approval, driven by promising results in a phase 2 clinical trial, signifies a potential paradigm shift with applications beyond melanoma. This innovative therapy, involving the extraction and replication of immune cells from a patient's tumour, represents a transformative advancement in cancer care. Despite potential side effects, experts emphasise its meaningful impact, particularly for patients who have exhausted conventional treatment options. For an in-depth exploration of Amtagvi's potential in cancer treatment, read the full story below: https://lnkd.in/eHbswTFk #molemap #fda #melanoma #cancertreatment

🌟 AbbVie's Teliso-V Shows Promise in NSCLC! 🩺 In a significant development, AbbVie seeks accelerated approval for its c-Met antibody-drug conjugate (ADC), Teliso-V, following a promising update from the Luminosity trial. Teliso-V demonstrated an impressive 35% overall response rate in a specific subset of patients with advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC) characterized by c-Met overexpression, representing approximately 25% of individuals with advanced EGFR wild type NSCLC. 📊 The Luminosity trial meticulously categorized patients based on c-Met expression levels, distinguishing between high and intermediate groups. Teliso-V exhibited a notable 35% response rate in the c-Met high group, with a slightly lower rate of 23% in the c-Met intermediate cohort. AbbVie's Chief Medical Officer, Dr Rupal Thakkar, highlights the even distribution of the targeted patient population between these two groups. #abbvie #TelisoV #LuminosityTrial #nsclc #MedicalAdvances #lifesciences

NEW from #ESMO2023 | #eNRGy: #zenocutuzumab in NRG1 fusion-positive #pancreatic ductal #adenocarcinoma 🎥 Alison Schram, MD, Memorial Sloan Kettering Cancer Center, discusses results from the Phase II #eNRGytrial (NCT02912949), which is assessing the safety, tolerability and anti-tumor activity of the #bispecificantibody #zenocutuzumab in patients with NRG1 fusion-positive #solidtumors Here, she discusses the encouraging results in patients with #pancreaticductaladenocarcinoma 🔬 The data shows a promising overall response rate, and the median duration of response (mDoR) was 9.1 months. 84% of patients had a greater than 50% decline in CA 19-9 from baseline 💡 Give it a watch to learn more 👉 https://lnkd.in/eqxryaCG #Oncology ESMO - European Society for Medical Oncology

The discovery and development of Herceptin (trastuzumab) 25 years ago can be recognised as a significant milestone in the journey toward precision medicine. Herceptin stands as an early example of targeted therapies in oncology, specifically targeting HER2-positive early breast cancer patients. We have since made tremendous strides in precision medicine, but there is still much work to be done on the testing front. Ineffective diagnostic pathways can result in missed opportunities for identifying eligible patients, therefore leading to missed treatment opportunities for patients. Our analysis of the impact of Clinical Practice Gaps (https://lnkd.in/epd6qkCT) published in the Journal of Clinical Oncology revealed that 29.2% of biomarker-positive patients are not prescribed the appropriate precision medicine therapy at the treatment decision stage of their journey. Through the enhancement of diagnostic accuracy and efficiency, we close the gap between available treatments and eligible patients, ultimately leading to improved patient outcomes. #PrecisionMedicine #Oncology #Diagnostics 

【Targeted Radiation Therapy: Balancing quality of life after treatment】 Like all medical treatments, cancer therapy often comes with side effects. Therefore, when doctors plan for cancer management, they consider not only the effectiveness of the treatment but also its side effects and the overall impact on the patient's quality of life. The medical community has developed Targeted Radiation Therapy, which combines targeted drugs with radiation therapy. This method targets cancer cells marked with specific biomarkers, thus minimizing the damage to healthy cells. The majority of the side effects during treatment are mild and manageable, such as fatigue, dry mouth, and nausea. To learn more about the latest treatment technologies that preserve patients' quality of life, be sure to watch the video featuring Dr. Kitty Law, a specialist in clinical oncology! Reference: Sartor O, et al. N Engl J Med. 2021;385(12):1091-1103 This video is supported by Novartis Pharmaceuticals (HK) Ltd. HK2406185640 #TargetedRadiationTherapy #CancerTreatment #CancerCell #HKSUO #ClinicalOncology #DrKittyLaw

New Bladder Cancer Data: Overall Survival Doubles ✨ A groundbreaking shift in advanced urothelial carcinoma treatment has emerged in the EV-302/KEYNOTE-A39 trial, showcasing the promising synergy of enfortumab vedotin and pembrolizumab. This combination nearly doubled the median progression-free survival (12.5 months versus 6.3 months, respectively; hazard ratio [HR] 0.45; 95% confidence interval [CI] 0.38–0.54; p<0.00001) And median overall survival (OS) also almost doubled (31.5 months versus 16.1 months, respectively; HR 0.47; 95% CI 0.38–0.58; p<0.00001) Compared with chemotherapy (cisplatin or carboplatin plus gemcitabine) at a median follow-up of 17.2 months in 886 patients with previously untreated, locally advanced, or metastatic urothelial carcinoma (LBA6). Will the combination of directive and immunotherapies rewrite the treatment textbooks? Share your thoughts in the comments section below 👇 #esmo2023 #esmo23 #esmo #oncology #pharma #biotech #competitiveintelligence #insights

Recently, the FDA approved the combination therapy of encorafenib and binimetinib for patients with metastatic non-small cell lung cancer (NSCLC) harboring the BRAF V600E mutation. This approval is based on data from the PHAROS Phase 2 clinical trial, which demonstrated high response rates in both treatment-naive and previously treated patients, with a 75% objective response rate (ORR) in treatment-naive patients. BRAF mutations are significant biomarkers in NSCLC and melanoma, guiding the development of targeted therapies that significantly improve patient outcomes. Genecast’s advanced liquid biopsy technology offers a non-invasive, highly accurate method for detecting BRAF mutations. This innovation revolutionizes cancer diagnosis and treatment by providing oncologists with real-time data for informed decision-making, ultimately enhancing patient survival rates and quality of life. Please check the article below : https://lnkd.in/eH5fD27u #Genecast #Enzyme #ADPS #LiquidBiopsy #CancerDiagnosis #MolecularDiagnostics #CancerDetection #NSCLC #Melanoma #BRAFmutation #PersonalizedMedicine #CancerResearch

Patients with ALK fusion-positive tumors have traditionally been excluded from clinical trials examining the efficacy of immunomodulatory agents due to reports that PD-1/PD-L1 therapies are ineffective. Kyle Strickland et al evaluated 3,393 lung cancers and found that ALK-positive lung adenocarcinomas are associated with a younger age, lower tumor mutational burden and higher PD-L1 expression compared to ALK-wild-type, EGFR mutated, and KRAS mutated lung adenocarcinomas. Our results highlight clinical trials evaluating novel immunotherapies should consider these unique patients. Learn more at #SITC2023, poster 513, on Friday, Nov. 3.